TRAILBLAZER-2, a Phase 3 study, has enrolled 1,600 participants. Prescreening with plasma p-tau-181 helped select people with both amyloid and tau pathology. A secondary prevention trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback